HALO

Halozyme Therapeutics Incorporated
51.21
-0.63 (-1.22%)

Halozyme Therapeutics Inc. (HALO) Fundamentals

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
SHARE INFORMATION
Market Cap$ 7,118,967,504
Shares Outstanding135,213,058
Float114,628,226
Percent Float84.78%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 443,310,000
Latest Fiscal EPS$ 2.75
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions852
Institutional Holdings Date2023-01-31
Institutional Bought Previous 3 Months12,009,596
Institutional Holdings Percent184.2%
Institutional Sold Previous 3 Months10,254,312
Insider Holdings Date2023-01-31
Insider Bought Previous 3 Months97,611
Insider Holdings Percent8.3
Insider Sold Previous 3 Months270,663
Insider Shares Owned11,281,998
TRADING INFO
52 Week High$ 59.46
52 Week Low$ 32.00
52 Week High Change$ 53.50
21 Day Moving Average$ 52.2957
21 Day Extended Moving Average$ 52.6647
50 Day Moving Average$ 54.921
50 Day Extended Moving Average$ 52.8463
200 Day Moving Average$ 47.2055
200 Day Extended Moving Average$ 47.8708
10 Day Average Volume977,975
20 Day Average Volume1,344,839
30 Day Average Volume1,200,996
50 Day Average Volume1,256,335
Alpha0.014223
Beta1.2217
Standard Deviation0.117349
R20.316227
7 Day Price Change$ 1.94
7 Day Percent Change3.83%
21 Day Price Change$ 2.31
21 Day Percent Change4.59%
30 Day Price Change$ -2.48
30 Day Percent Change-4.5%
Month to Date Price Change$ 0.88
Month to Date Percent Change1.7%
Quarter to Date Price Change$ -4.25
Quarter to Date Percent Change-7.47%
180 Day Price Change$ 5.17
180 Day Percent Change10.89%
200 Day Price Change$ 4.45
200 Day Percent Change9.23%
Year to Date Price Change$ -4.25
Year to Date Percent Change-7.47%

Halozyme Therapeutics Inc. (HALO) Key Ratios

PROFITABILITY
EBIT Margin42.6%
EBITDA Margin50.1%
Pre-Tax Profit Margin13.3%
Profit Margin Count30.18%
Gross Margin79.5%
Profit Margin TOT30.18%
INCOME STATEMENTS
Revenue$ 478,620,000
Revenue Per Share$ 3.5397
Revenue (3 Years)$ 34.54
Revenue (5 Years)$ 13.47
FINANCIAL STRENGTH
Price to Tangible Book-6.80
Total Debt To Equity15.50
Int Coverage17.10
Current Ratio6.00
Leverage Ratio7.40
Quick Ratio4.60
Long Term Debt To Capital0.94
VALUATION MEASURES
PE Ratio35.30
Enterprise Value$ 8,357,854,503
Price to Sales14.8739
Price to Free Cash-8.40
PE High Last 5 Years62.00
Price To Book73.40
Price To Cash Flow31.10
PE Low Last 5 Years-25.40
Price to Tangible Book-6.80
MANAGEMENT EFFECTIVENESS
Receivables Turnover1.40
Invoice Turnover1.50
Assets Turnover0.20
Return Assets13.85
Return on Equity111.55
Return on Capital16.26

Halozyme Therapeutics Inc. (HALO) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOHelen I. Torley
Emplyoees145
Last AuditUE
CIK0001159036
IndustryBiotechnology
SectorHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing(325414)
CONTACT INFO
Address11388 Sorrento Valley Road
San Diego, CA 92121
Websitehttps://www.halozyme.com
Facsimile+1 858 704-8311
Telephone+1 858 794-8889
Emailir@halozyme.com


Your Recent History
NASDAQ
HALO
Halozyme T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.